GeoVax Labs (GOVX) Projected to Release Earnings on Monday

GeoVax Labs (NASDAQ:GOVX) is expected to be announcing its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect the company to announce earnings of ($2.16) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.62) EPS for the quarter, beating the consensus estimate of ($3.84) by $1.22. On average, analysts expect GeoVax Labs to post $-9 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $0.97 on Monday. The company has a market cap of $3.38 million, a P/E ratio of -0.05 and a beta of 3.68. GeoVax Labs has a 12 month low of $0.82 and a 12 month high of $23.10. The company has a 50-day moving average of $1.59 and a 200-day moving average of $1.96.

Analysts Set New Price Targets

A number of research firms recently issued reports on GOVX. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Tuesday, April 21st. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $150.00.

Institutional Trading of GeoVax Labs

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in GeoVax Labs during the 1st quarter valued at about $27,000. HRT Financial LP purchased a new stake in shares of GeoVax Labs during the fourth quarter valued at $31,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the third quarter valued at approximately $253,000. Finally, Renaissance Technologies LLC acquired a new stake in GeoVax Labs during the 4th quarter worth about $104,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.